A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
13 02 2020
Historique:
received: 02 06 2019
accepted: 05 11 2019
pubmed: 9 11 2019
medline: 22 7 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

Unintentional transduction of B-cell acute lymphoblastic leukemia blasts during CART19 manufacturing can lead to CAR19+ leukemic cells (CARB19) that are resistant to CART19 killing. We developed an anti-CAR19 idiotype chimeric antigen receptor (αCAR19) to specifically recognize CAR19+ cells. αCAR19 CAR T cells efficiently lysed CARB19 cells in vitro and in a primary leukemia-derived xenograft model. We further showed that αCAR19-CART cells could be used as an "antidote" to deplete CART19 cells to reduce long-term side effects, such as B-cell aplasia.

Identifiants

pubmed: 31703119
pii: S0006-4971(20)62252-2
doi: 10.1182/blood.2019001859
pmc: PMC7019191
doi:

Substances chimiques

Antigens, CD19 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

505-509

Subventions

Organisme : NCI NIH HHS
ID : K99 CA212302
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA214278
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA212302
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Clin Invest. 2016 Oct 3;126(10):3814-3826
pubmed: 27571406
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Nat Med. 2018 Oct;24(10):1504-1506
pubmed: 30275569
PLoS One. 2013;8(3):e57838
pubmed: 23469246
Leukemia. 2004 Apr;18(4):676-84
pubmed: 14961035
Blood. 2013 Feb 14;121(7):1165-74
pubmed: 23243285
N Engl J Med. 2011 Nov 3;365(18):1673-83
pubmed: 22047558
Leuk Lymphoma. 2018 Sep;59(9):2040-2055
pubmed: 29165008
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
J Clin Invest. 2016 Nov 1;126(11):4262-4272
pubmed: 27760047
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Nat Med. 2018 Oct;24(10):1499-1503
pubmed: 30275568
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Blood. 2011 Aug 4;118(5):1255-63
pubmed: 21653320
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
Comput Struct Biotechnol J. 2016 Sep 28;14:357-362
pubmed: 27761200
Blood. 2014 Apr 10;123(15):2343-54
pubmed: 24596416

Auteurs

Marco Ruella (M)

Center for Cellular Immunotherapies and.
Department of Medicine, Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

David M Barrett (DM)

Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.

Olga Shestova (O)

Center for Cellular Immunotherapies and.

Jessica Perazzelli (J)

Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.

Avery D Posey (AD)

Center for Cellular Immunotherapies and.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA; and.

Seok Jae Hong (SJ)

Center for Cellular Immunotherapies and.

Miroslaw Kozlowski (M)

Center for Cellular Immunotherapies and.

Simon F Lacey (SF)

Center for Cellular Immunotherapies and.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

J Joseph Melenhorst (JJ)

Center for Cellular Immunotherapies and.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Carl H June (CH)

Center for Cellular Immunotherapies and.
Department of Medicine, Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Saar I Gill (SI)

Center for Cellular Immunotherapies and.
Department of Medicine, Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH